X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Holly Campbell

Holly Campbell Holly Campbell is a deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.

Recent Posts

Video: PhRMA CEO discusses medicine costs with CNBC's Squawk Box

By Holly Campbell  |    July 31, 2017
PhRMA president and CEO Stephen J. Ubl joined Squawk Box this morning to put medicine costs and spending in context, the biopharmaceutical supply chain and policy solutions to address cost...   Read More

New data put medicine costs and spending in context

By Holly Campbell  |    June 26, 2017
We are in a new era of medicine where breakthrough science is transforming patient care and enabling us to more effectively treat chronic diseases, like cancer and diabetes, which are the biggest...   Read More

PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines

By Holly Campbell  |    June 2, 2017
    The following op-ed was authored by PhRMA president and CEO Stephen J. Ubl and published on Forbes here on June 2, 2017. The way our health care system currently pays for prescription...   Read More

ICYMI: Avalere and FasterCures develop new value framework from patient perspective

By Holly Campbell  |    May 31, 2017
In case you missed it, a year-long collaboration between Avalere and FasterCures has resulted in the first value framework from the patient perspective. Unlike other frameworks which include...   Read More

ICYMI: Innovative payment models helping provide patient access to new medicines

By Holly Campbell  |    May 5, 2017
As we continue to make remarkable strides to treat our most costly and challenging diseases, there is a renewed focus on ensuring patients have access to the most innovative medicines....   Read More

4 Things to know about the QuintilesIMS Medicines Use and Spending in the U.S. report

By Holly Campbell  |    May 4, 2017
We have seen a deluge of data recently from government actuaries and pharmacy benefit managers showing a dramatic slowdown in medicine spending growth. And the QuintilesIMS Medicines Use and...   Read More

New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price

By Holly Campbell  |    March 29, 2017
More than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on full list prices, according to a new analysis from Amundsen Consulting, a division of...   Read More

ICYMI – 3 new reports show dramatic slowdown in medicine spending growth

By Holly Campbell  |    February 17, 2017
Newly released government actuary and pharmacy benefit manager data confirm previous projections of a significant decline in medicine spending growth. After accounting for discounts and rebates,...   Read More

PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check

By Holly Campbell  |    February 9, 2017
Following the biopharmaceutical industry’s recent meeting with President  Donald J. Trump, PhRMA president and CEO Stephen J. Ubl joined Dan Diamond on POLITICO’s Pulse Check podcast to discuss...   Read More

VIDEO: PhRMA CEO joins Fox Business anchor Neil Cavuto to discuss personal connection to value of innovation and White House meeting

By Holly Campbell  |    February 6, 2017
PhRMA president and CEO Stephen J. Ubl recently spoke with FOX Business anchor Neil Cavuto on his personal connection to the value of medical technology with his son’s type 1 diabetes diagnosis,...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates